首页> 外文期刊>The journal of clinical psychiatry >Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment Failure in Persons With Schizophrenia
【24h】

Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment Failure in Persons With Schizophrenia

机译:帕潘立酮棕榈酸酯用于证明有效性(PRIDE)研究的设计和原理:每月一次帕潘立酮棕榈酸酯与每日口服抗精神病药物治疗的新型比较试验,用于延迟精神分裂症患者的治疗失败时间

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Public health considerations require that clinical trials address the complex "real-world" needs of patients with chronic illnesses. This is particularly true for persons with schizophrenia, whose management is frequently complicated by factors such as comorbid substance abuse, homelessness, and contact with the criminal justice system. In addition, barriers to obtaining health care in the United States often prevent successful community reentry and optimal patient management. Further, nonadherence to treatment is common, and this reinforces cycles of relapse and recidivism.
机译:背景:出于公共卫生考虑,临床试验必须满足慢性病患者复杂的“现实世界”需求。对于精神分裂症患者尤其如此,精神分裂症患者的管理常常由于诸如共病滥用药物,无家可归以及与刑事司法系统接触等因素而变得复杂。另外,在美国获得医疗保健的障碍常常阻碍成功的社区再入和最佳的患者管理。此外,不坚持治疗是很常见的,这加剧了复发和复发的周期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号